Curiteva acquired FossiLabs, developer of Fused Filament Fabrication 3D-printed PEEK implants. The start-up has created a proprietary process to fabricate scaffolding structures with controlled areas of macroporosity and hydrophilicity to increase surface area and promote osseointegration.
Curiteva believes that its products will be the first 3D-printed PEEK interbody devices offering an interconnected porous structure and a bioactive surface for optimal healing and radiographic evaluation.
Curiteva recently closed a private funding round of $20 million to support its pursuit of new technology.
“The acquisition of FossiLabs reflects Curiteva’s continued commitment to developing and investing in disruptive technologies. Our plan is to work diligently to execute on a robust domestic and international IP strategy, engage key opinion leaders in optimizing implant design, and submit for FDA 510(k) clearance in 2021.” – Eric Linder, Chief Technology Officer
Curiteva acquired FossiLabs, developer of Fused Filament Fabrication 3D-printed PEEK implants. The start-up has created a proprietary process to fabricate scaffolding structures with controlled areas of macroporosity and hydrophilicity to increase surface area and promote osseointegration.
Curiteva believes that its products will be the...
Curiteva acquired FossiLabs, developer of Fused Filament Fabrication 3D-printed PEEK implants. The start-up has created a proprietary process to fabricate scaffolding structures with controlled areas of macroporosity and hydrophilicity to increase surface area and promote osseointegration.
Curiteva believes that its products will be the first 3D-printed PEEK interbody devices offering an interconnected porous structure and a bioactive surface for optimal healing and radiographic evaluation.
Curiteva recently closed a private funding round of $20 million to support its pursuit of new technology.
“The acquisition of FossiLabs reflects Curiteva’s continued commitment to developing and investing in disruptive technologies. Our plan is to work diligently to execute on a robust domestic and international IP strategy, engage key opinion leaders in optimizing implant design, and submit for FDA 510(k) clearance in 2021.” – Eric Linder, Chief Technology Officer
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
